Trading IdeasFundamentals

Gufic Biosciences Ltd.

NSE: GUFICBIO · Pharmaceuticals · sector

₹407.35NSE close 2026-10-26

Key numbers

Market cap₹4,085 cr
Price₹407.35
52w high / low₹468 / ₹268
P/E55.6xSector median 27.9x
P/B6.1xSector median 2.9x
Book value₹66.3
Dividend yield0.03%Sector median 0.48%
ROE11.6%Sector median 11.7%
ROCE12.9%Sector median 12.3%
OPM16.8%Sector median 14.0%
Debt / equity0.58xSector median 0.16x
EV/EBITDA26.7xSector median 18.6x
Interest cover3.7x
Current ratio1.55x
Sales growth 3y+11.0%Sector median +9.6%
Profit growth 3y-7.0%Sector median +13.3%
PEG–

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹474.25 · low ₹277.10
Sep 2024Apr 2025Oct 2025Apr 2026

Quarterly results

₹ crSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue204208205224237231252261
EBITDA3934263338334747
OPM %18.9%16.3%12.9%14.9%16.0%14.3%18.7%17.9%
Other income020121-10
Net profit221981317122222
EPS (₹)2.171.930.771.301.681.242.182.22
Revenue YoY+16.1%+11.4%+22.8%+16.6%
Profit YoY-22.7%-35.7%+183.7%+70.7%

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ crFY22FY23FY24FY25FY26TTM
Revenue779691807820944981
EBITDA146135146135151165
Net profit968086706473
EPS (₹)9.898.228.746.956.407.32
Revenue growth-11.4%+16.8%+1.6%+15.1%+16.7%
Profit growth-16.8%+8.1%-19.1%-7.8%+18.7%
Dividend / share (₹)0.100.100.100.100.10
Compounded growth3 years5 yearsLast 12 months
Sales+11.0%+14.1%+16.7%
Net profit-7.0%+7.7%+18.7%
EPS-8.0%+7.0%–
Share price–-7.0% (2y)+11.4%

Balance sheet

₹ crFY22FY23FY24FY25FY26
Shareholders' equity–348533601665
Borrowings–311317310385
Cash & equivalents–47132976
Total assets–8611,0931,1691,342
Fixed assets–159153500485
Capital work in progress–1703072222
Investments–1222
Receivables–205330315297
Inventory–183200217324
Payables–130166159199

Year-end figures from the March annual filing.

Cash flow

₹ crFY22FY23FY24FY25FY26
Cash from operations104-27-712345
Cash from investing-96-191-102-71-31
Cash from financing-323482-3732
Capex891881137631
Free cash flow16-214-1204714

Free cash flow = cash from operations − capex.

Ratios by year

₹ crFY22FY23FY24FY25FY26
ROE %–22.9%16.2%11.6%9.7%
ROCE %–17.4%15.4%12.9%11.7%
Debtor days–109149140115
Inventory days–202188211281
Payable days–143156155172
Cash conversion cycle (days)–168181196224
Working capital days–93103106110

Shareholding

Holder% (2026-09-30)
Promoters72.50%
FIIs0.45%
DIIs3.38%
of which Mutual funds3.03%
Public (non-institutions)23.67%
QuarterDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters %72.51%72.51%72.51%72.50%72.50%72.50%72.50%72.50%
Promoter group%
Jayesh Pannalal Choksi24.62%
Zircon Teconica Private Limited20.47%
Gufic Private Limited10.16%
Vipula Jayesh Choksi10.01%
Pranav Jayesh Choksi7.25%
Pooja Pranav Choksi0.00%
Meira Pranav Choksi0.00%
Shiv Pranav Choksi0.00%
Rita Ashok Shah0.00%
Kshama Vipul Choksi0.00%
Forum Ameet Shah0.00%
Jayesh Pannalal Choksi (HUF)0.00%
Uma Lalit Trivedi0.00%
Dhan Pankaj Zaveri0.00%
Deepika Milan Barot0.00%
Public holders above 1%%
Motilal Oswal Financial Services Ltd3.32%
ICICI Prudential Multi CAP Fund1.65%
Jagdish N Master1.19%
Girish Gulati (HUF)1.00%

29,726 shareholders. Pledged: 0.00% of promoter shares.

Peers in Pharmaceuticals

CompanyMarket capP/EP/BROEROCEOPMSales 3yDiv yield
SUNPHARMA₹4,17,478 cr34.5x5.0x15.5%18.7%28.6%+10.0%0.94%
DIVISLAB₹2,39,825 cr82.1x14.3x18.4%23.0%34.7%+10.8%0.34%
TORNTPHARM₹1,53,999 cr72.7x18.4x27.3%15.1%32.3%+13.3%0.84%
ZYDUSLIFE₹1,15,808 cr25.9x4.3x17.7%16.8%27.2%+16.4%0.95%
LAURUSLABS₹1,11,232 cr101.6x21.0x22.4%20.8%28.0%+4.1%0.08%
CIPLA₹1,09,464 cr32.5x3.2x10.3%13.2%17.7%+7.4%1.18%
DRREDDY₹1,09,460 cr33.9x2.9x9.0%10.1%15.5%+11.0%0.61%
MANKIND₹95,486 cr46.7x5.9x13.4%13.8%25.1%+17.7%0.04%
AUROPHARMA₹91,489 cr24.9x2.4x10.5%12.8%20.0%+10.6%0.26%
GUFICBIO₹4,085 cr55.6x6.1x11.6%12.9%16.8%+11.0%0.03%

All 185 companies in Pharmaceuticals →

Dividends & corporate actions

Ex-dateActionDetail
2026-08-28DividendDividend - Re 0.10 Per Share
2025-09-22DividendDividend - Re 0.10 Per Share
2024-09-17DividendAnnual General Meetingdividend - Re 0.10 Per Share
2023-09-21DividendAnnual General Meeting/Dividend - Re 0.10 Per Share
2022-08-24DividendAnnual General Meeting/Dividend - Rs 0.10 Per Sh
2021-09-09DividendAnnual General Meeting/Dividend - Rs 0.10 Per Share
2020-11-03DividendAnnual General Meeting/Dividend - Rs 0.05 Per Share
2019-09-20DividendAnnual General Meeting/Dividend - Rs 0.05 Per Equity Share
2018-09-19DividendAnnual General Meeting/Dividend Re 0.05 Per Share
2017-08-28DividendAnnual General Meeting/Dividend - Re 0.05 Per Share
2016-09-19DividendAnnual General Meeting/Dividend - Re 0.05 Per Share
2015-09-22DividendAnnual General Meeting/ Dividend - Re 0.05/- Per Share
2014-09-18DividendAnnual General Meeting / Final Dividend - Re 0.05/- Per Share
2013-09-19DividendAnnual General Meeting / Dividend - Re 0.05/- Per Share (Bc Dates Revised)
2012-08-16DividendAnnual General Meeting/ Dividend Rs. 0.05 Per Share
2011-09-16DividendAnnual General Meeting And Dividend Re.0.05 Per Share
2010-09-20DividendAnnual General Meeting And Dividend Re.0.05 Per Share
2009-09-17OtherAgm/Div-Re.0.05 Per Share
2008-12-11DividendAgm/Dividend - 5%
2008-03-19DividendAgm/Dividend - 5%

Documents

Links go to the original files on the exchange website.

About the company

SectorHealthcare
IndustryPharmaceuticals
Sub-industryPharmaceuticals
SymbolGUFICBIO
BSE code509079
ISININE742B01025
Face value₹1.0
Incorporated1984-07-23
Websitewww.gufic.com
Plants (India / abroad)3 / 0

From the company's filings (BRSR FY26).

Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.